$INDP
Indaptus Therapeutics, Inc. Stock $indp

$indp Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-Q Financial Statement

#000149315222031392 Filed on November 10, 2022

Income Statement

Concept	2022 Q4	2022 Q3	2021 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.175M	$1.943M	$2.670M
YoY Change	-4.34%	-27.24%	74.64%
% of Gross Profit
Research & Development	$1.912M	$1.610M	$697.7K
YoY Change	102.39%	130.7%	-66.97%
% of Gross Profit
Depreciation & Amortization	$320.00	$390.00	$440.00
YoY Change	-39.62%	-11.36%	-99.85%
% of Gross Profit
Operating Expenses	$4.087M	$3.553M	$3.368M
YoY Change	26.99%	5.48%	-7.5%
Operating Profit		-$3.553M	-$3.368M
YoY Change		5.48%
Interest Expense			$830.00
YoY Change			-101.46%
% of Operating Profit
Other Income/Expense, Net	$431.3K	$86.18K	$827.00
YoY Change		10321.28%
Pretax Income	-$3.656M	-$3.466M	-$3.367M
YoY Change	13.66%	2.95%	-8.95%
Income Tax
% Of Pretax Income
Net Earnings	-$3.656M	-$3.466M	-$3.367M
YoY Change	13.66%	2.95%	-9.97%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.42	-$0.81
Diluted Earnings Per Share	-$0.44	-$419.7K	-$805.4K
COMMON SHARES
Basic Shares Outstanding	8.259M shares	8.259M shares	4.181M shares
Diluted Shares Outstanding		8.259M shares

Balance Sheet

Concept	2022 Q4	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.43M	$28.46M	$41.86M
YoY Change	-32.45%	-32.01%	145.12%
Cash & Equivalents	$9.627M	$6.718M	$41.86M
Short-Term Investments	$16.81M	$21.74M
Other Short-Term Assets	$811.4K	$1.133M	$1.998M
YoY Change	-35.35%	-43.26%	227.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$27.24M	$29.59M	$43.85M
YoY Change	-32.54%	-32.52%	147.98%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.019K	$2.340K	$4.340K
YoY Change	-46.87%	-46.08%	-99.84%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$738.3K	$754.7K
YoY Change	4380.49%
Total Long-Term Assets	$819.6K	$859.3K	$4.340K
YoY Change	332.8%	19700.05%	-99.93%
TOTAL ASSETS
Total Short-Term Assets	$27.24M	$29.59M	$43.85M
Total Long-Term Assets	$819.6K	$859.3K	$4.340K
Total Assets	$28.06M	$30.45M	$43.86M
YoY Change	-30.84%	-30.57%	82.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.378M	$1.246M	$5.780M
YoY Change	-47.75%	-78.44%	988.55%
Accrued Expenses	$80.49K	$98.63K
YoY Change	-16.56%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.433M	$2.881M	$5.780M
YoY Change	-25.43%	-50.16%	27.04%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$4.950K
YoY Change	-100.0%
Total Long-Term Liabilities		$4.949K	$0.00
YoY Change			-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.433M	$2.881M	$5.780M
Total Long-Term Liabilities		$4.949K	$0.00
Total Liabilities	$3.433M	$2.886M	$5.780M
YoY Change	-26.59%	-50.08%	-3.0%
SHAREHOLDERS EQUITY
Retained Earnings	-$30.00M	-$26.30M	-$12.45M
YoY Change	91.44%	111.17%
Common Stock	$84.01K	$82.59K
YoY Change	1.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$24.63M	$27.57M	$38.08M
YoY Change
Total Liabilities & Shareholders Equity	$28.06M	$30.45M	$43.86M
YoY Change	-30.84%	-30.57%	82.47%

Cashflow Statement

Concept	2022 Q4	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$3.656M	-$3.466M	-$3.367M
YoY Change	13.66%	2.95%	-9.97%
Depreciation, Depletion And Amortization	$320.00	$390.00	$440.00
YoY Change	-39.62%	-11.36%	-99.85%
Cash From Operating Activities	-$2.211M	-$4.602M	-$5.631M
YoY Change	-37.54%	-18.27%	175.46%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$1.650K
YoY Change		-100.0%	-87.31%
Acquisitions
YoY Change
Other Investing Activities	$5.120M	-$2.939M
YoY Change	1033.64%
Cash From Investing Activities	$5.120M	-$2.939M	-$1.650K
YoY Change	1033.64%	178024.85%	-87.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	0.000	42.52M
YoY Change	-100.0%	-100.0%	701.89%
NET CHANGE
Cash From Operating Activities	-2.211M	-4.602M	-5.631M
Cash From Investing Activities	5.120M	-2.939M	-1.650K
Cash From Financing Activities	0.000	0.000	42.52M
Net Change In Cash	2.909M	-7.541M	36.89M
YoY Change	-206.73%	-120.44%	1036.54%
FREE CASH FLOW
Cash From Operating Activities	-$2.211M	-$4.602M	-$5.631M
Capital Expenditures	$0.00	$0.00	-$1.650K
Free Cash Flow	-$2.211M	-$4.602M	-$5.629M
YoY Change	-37.54%	-18.25%	177.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001857044
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q3	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent		usd
CY2022Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax		usd
CY2021Q3	INDP	Reclassification Adjustment For Realized Gain On Available For Sale Securities Included In Net Loss ReclassificationAdjustmentForRealizedGainOnAvailableForSaleSecuritiesIncludedInNetLoss		usd
	INDP	Reclassification Adjustment For Realized Gain On Available For Sale Securities Included In Net Loss ReclassificationAdjustmentForRealizedGainOnAvailableForSaleSecuritiesIncludedInNetLoss		usd
CY2021Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax		usd
CY2021Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain		usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss		usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets		usd
	INDP	Increase Decrease In Operating Lease Right Of Use Asset And Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet		usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments		usd
	INDP	Proceeds From Merger ProceedsFromMerger		usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
	INDP	Proceeds From Issuanceof Pre Funded Warrantsand Warrants ProceedsFromIssuanceofPreFundedWarrantsandWarrants		usd
	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	INDP	Proceeds From Simple Agreementsfor Futrue Equity ProceedsFromSimpleAgreementsforFutrueEquity		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	INDP	Conversion Of Preferred Stock ConversionOfPreferredStock		usd
	INDP	Conversion Of Simple Agreementsfor Futrue Equity ConversionOfSimpleAgreementsforFutrueEquity		usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1		usd
	INDP	Release Of Deposit Upon Closing Of Merger ReleaseOfDepositUponClosingOfMerger		usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2022Q3	us-gaap	Other Receivables OtherReceivables		usd
CY2021Q4	INDP	Delaware Franchise Taxes Payable Current DelawareFranchiseTaxesPayableCurrent		usd
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40652
	dei	Entity Registrant Name EntityRegistrantName	Indaptus Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	86-3158720
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 Columbus Circle
	dei	Entity Address Address Line2 EntityAddressAddressLine2	15th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
	dei	City Area Code CityAreaCode	(646)
	dei	Local Phone Number LocalPhoneNumber	427-2727
	dei	Security12b Title Security12bTitle	Common stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	INDP
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8258597	shares
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6718213	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39132165	usd
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	21742040	usd
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	148400	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1133392	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1106653	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	29593645	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	40387218	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2340	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3800	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	102254	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	169088	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	754728	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	16477	usd
CY2022Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	859322	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	189365	usd
CY2022Q3	us-gaap	Assets Assets	30452967	usd
CY2021Q4	us-gaap	Assets Assets	40576583	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2782084	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4507676	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	98625	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	96465	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2880709	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4604141	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4949	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	72862	usd
CY2022Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4949	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	72862	usd
CY2022Q3	us-gaap	Liabilities Liabilities	2885658	usd
CY2021Q4	us-gaap	Liabilities Liabilities	4677003	usd
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8258597	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8258597	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8258597	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8258597	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	82586	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	82586	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	53807500	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	51487881	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26337908	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-15670887	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	15131	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27567309	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35899580	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30452967	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	40576583	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1609554	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	697674	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4412817	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1578512	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1942995	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2670317	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6411066	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2932100	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3552549	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	3367991	usd
	us-gaap	Operating Expenses OperatingExpenses	10823883	usd
	us-gaap	Operating Expenses OperatingExpenses	4510612	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3552549	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3367991	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10823883	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4510612	usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	86184	usd
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	827	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	156862	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	15548	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466365	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3367164	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10667021	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4495064	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.67
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8258597	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4180744	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8258597	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2692770	shares
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466365	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3367164	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10667021	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4495064	usd
CY2022Q3	INDP	Reclassification Adjustment For Realized Gain On Available For Sale Securities Included In Net Loss ReclassificationAdjustmentForRealizedGainOnAvailableForSaleSecuritiesIncludedInNetLoss	-7836	usd
	INDP	Reclassification Adjustment For Realized Gain On Available For Sale Securities Included In Net Loss ReclassificationAdjustmentForRealizedGainOnAvailableForSaleSecuritiesIncludedInNetLoss	-7836	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	49904	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	22967	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3424297	usd
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3367164	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10651890	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4495064	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-237701	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20445	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-612421	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-829677	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	20673	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-515479	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-1324483	usd
CY2021Q3	INDP	Stock Issued During Period Value Conversion Of Safe Agreements StockIssuedDuringPeriodValueConversionOfSafeAgreements	6417129	usd
CY2021Q3	INDP	Stock Issued During Period Value Issuance Of Common Stock Upon Merger Netof Transaction Costs StockIssuedDuringPeriodValueIssuanceOfCommonStockUponMergerNetofTransactionCosts	8264820	usd
CY2021Q3	INDP	Stock Issued During Period Value Issuance Of Prefunded Warrantsand Warrants StockIssuedDuringPeriodValueIssuanceOfPrefundedWarrantsandWarrants	27266129	usd
CY2021Q3	INDP	Stock Issued During Period Value Excercise Of Prepaid Warrants StockIssuedDuringPeriodValueExcerciseOfPrepaidWarrants	27273	usd
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	795338	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3367164	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	38079042	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	35899580	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	831183	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9221	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3365154	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	33356388	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	904395	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-17716	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-3835502	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30407565	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	584041	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	49904	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Reclassification Adjustment From Aoci For Sale Of Securities Net Of Tax OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax	-7836	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3466365	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	27567309	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10667021	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4495064	usd
	us-gaap	Depreciation Depreciation	1460	usd
	us-gaap	Depreciation Depreciation	868	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2319619	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	836456	usd
	us-gaap	Debt Securities Available For Sale Realized Gain DebtSecuritiesAvailableForSaleRealizedGain	24155	usd
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	7836	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	26739	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1128933	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1725592	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2964147	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	738251	usd
	INDP	Increase Decrease In Operating Lease Right Of Use Asset And Liability Net IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet	1081	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10867434	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7750820	usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	172555	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3854	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	23719073	usd
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	2000000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21546518	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3854	usd
	INDP	Proceeds From Merger ProceedsFromMerger	16346622	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	665627	usd
	INDP	Proceeds From Issuanceof Pre Funded Warrantsand Warrants ProceedsFromIssuanceofPreFundedWarrantsandWarrants	29972727	usd
	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	2706598	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	27273	usd
	INDP	Proceeds From Simple Agreementsfor Futrue Equity ProceedsFromSimpleAgreementsforFutrueEquity	5000000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	47974397	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-32413952	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	40219723	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39132165	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1637499	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	6718213	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41857222	usd
	INDP	Conversion Of Preferred Stock ConversionOfPreferredStock	8359	usd
	INDP	Conversion Of Simple Agreementsfor Futrue Equity ConversionOfSimpleAgreementsforFutrueEquity	6417129	usd
	us-gaap	Liabilities Assumed1 LiabilitiesAssumed1	7616175	usd
	INDP	Release Of Deposit Upon Closing Of Merger ReleaseOfDepositUponClosingOfMerger	200000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2400	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	800	usd
	INDP	Cash Received For Interest Earned On Deposits CashReceivedForInterestEarnedOnDeposits	70353	usd
	INDP	Cash Received For Interest Earned On Deposits CashReceivedForInterestEarnedOnDeposits	2362	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_800_eus-gaap--NatureOfOperations_zfh1Fdy3Ldr3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1: <span id="xdx_827_zSUqzN7PNwm6">GENERAL</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indaptus Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., (collectively, the “Company”), is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted product that activates both innate and adaptive anti-tumor and anti-viral immune responses.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indaptus Therapeutics, Inc. (“Indaptus”), formerly “Intec Parent Inc.”, was established and incorporated in Delaware on February 24, 2021, as a private Delaware corporation and wholly-owned subsidiary of Intec Pharma Ltd., (“Intec Israel”), a former publicly traded company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 3, 2021, Indaptus completed its merger with Decoy Biosystems, Inc., (“Decoy”), following the satisfaction or waiver of the conditions set forth in the Agreement and Plan of Merger, dated as of March 15, 2021 among Indaptus, Decoy, Intec Israel, Domestication Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of Indaptus, and Dillon Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Indaptus (“the Merger Sub”), pursuant to which Merger Sub merged with and into Decoy, with Decoy surviving as a wholly-owned subsidiary of Indaptus (the “Merger”) and the business conducted by Decoy became the business conducted by Indaptus.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also, in connection with the Merger, Indaptus changed its name from “Intec Parent, Inc.” to “Indaptus Therapeutics, Inc.”. Following completion of the Merger, shares of Indaptus common stock commenced trading at market open on August 4, 2021, on the Nasdaq Capital Market under the name “Indaptus Therapeutics, Inc.” and under the symbol “INDP”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the Merger, on July 23, 2021, Indaptus entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor, pursuant to which Indaptus agreed to sell and issue, in a private placement (the “Private Placement”), pre-funded warrants and warrants for total net proceeds of approximately $<span id="xdx_90C_ecustom--ProceedsFromIssuanceOfPreFundedWarrantsGross_pn5n6_c20210722__20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zg6fZ4JOl2O6" title="Total net proceeds from issuance of pre-funded warrants and warrants to purchase Indaptus common stock">27.3</span> million, after deducting the placement agent’s fees and other estimated offering expenses payable by Indaptus in the amount of approximately $<span id="xdx_903_ecustom--IssuanceExpenses_pn5n6_c20210722__20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zDjS2WIxXi9b" title="Issuance expenses">2.7</span> million. In September 2021, the pre-funded warrant was fully exercised. Each warrant is exercisable at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zlPmZexyin3l" title="Warrant is exercisable price">11.00</span> per share and has a term of five and one-half years from the date of issuance. In addition, in connection with the Private Placement, Indaptus issued to the placement agent a warrant to purchase <span id="xdx_907_ecustom--NumberOfWarrantsIssuedToPlacementAgent_iI_c20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z4pxF8drum7c" title="Number of warrants issued to the placement agent">136,364</span> shares of Indaptus’ common stock at an exercise price of $<span id="xdx_902_ecustom--ExercisePriceOfWarrantIssuedToPlacementAgent_iI_c20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zFUxmQuzUcXc" title="Exercise price of warrant issued to the placement agent">13.75</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On June 1, 2022, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) which was amended on September 1, 2022 with H.C. Wainwright & Co., LLC, as sales agent (“Wainwright”), pursuant to which the Company may offer and sell, from time to time through Wainwright, shares of the Company’s common stock, par value $<span id="xdx_903_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220601__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zCd6qCcRyQJ1" title="Common stock, par value">0.01</span> per share, for aggregate gross proceeds of up to $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOfCommonStock_pn5n6_c20220601__20220601__us-gaap--TypeOfArrangementAxis__custom--AtTheMarketOfferingAgreementMember__dei--LegalEntityAxis__custom--HCWainwrightAndCoLLCMember_zgiGQYO0jYXh" title="Common stock gross proceeds">6.3</span> million. </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The issuance and sale of common stock by the Company under the <span style="background-color: white">ATM Agreement</span> is being made pursuant to the Company’s effective “shelf” registration statement on Form S-3 filed with the SEC on September 1, 2022 and declared effective on September 9, 2022. The Company’s effective “shelf” registration statement on Form S-3 is under General Instruction I.B.6 to Form S-3, or the Baby Shelf Rule.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited to, the need for successful development of products, the need for additional capital (or financing) to fund operating losses (see below), competition from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence on key individuals.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The COVID-19 pandemic has resulted in significant financial market volatility and uncertainty in the past year. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of its product candidates and the conduct of future clinical trials. For example, the pandemic has caused our good manufacturing practice (“GMP”) process to take longer than expected. In addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company’s product candidates. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact its short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. While it is unknown how long these conditions will last and what the complete financial effect will be to the Company, capital raise efforts and additional development of the Company’s technologies may be negatively affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Going concern and management’s plans</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has incurred net losses and utilized cash in operations since inception, has an accumulated deficit as of September 30, 2022 of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pn5n6_di_c20220930_zIua9Rrj5XPk" title="Accumulated deficit">26.3</span> million, and expects to incur future additional losses as clinical testing and commercialization of the Company’s product candidates will require significant additional financing. The Company believes it has adequate cash and marketable securities to fund its operations for at least one year after the date of issuance of these unaudited condensed consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management plans to raise additional capital through equity and/or debt financings, or other capital sources, including potential collaborations, licenses, and other similar arrangements. However, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company’s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the conflict between Russia and Ukraine and the ongoing COVID-19 pandemic. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its research and development programs or other operations. If any of these events occur, the Company’s ability to achieve the development and commercialization goals would be adversely affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26300000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zZcmiQu0yab8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_86B_zTwt6nqlzwW7">Use of estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the unaudited condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the unaudited condensed consolidated financial statements; therefore, actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i> </i></span></p>
CY2022Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	21742040	usd
CY2022Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	42068	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	15131	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	836833	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	945023	usd
CY2022Q3	INDP	Prepaid Research And Development PrepaidResearchAndDevelopment	248719	usd
CY2021Q4	INDP	Prepaid Research And Development PrepaidResearchAndDevelopment	127643	usd
CY2021Q4	us-gaap	Other Receivables OtherReceivables	21056	usd
CY2022Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	47840	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	12931	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1133392	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1106653	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1246240	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2637806	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	791382	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1371136	usd
CY2022Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	228811	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	139871	usd
CY2022Q3	INDP	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	241009	usd
CY2021Q4	INDP	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	135751	usd
CY2022Q3	INDP	Accrued Board Fees Current AccruedBoardFeesCurrent	116000	usd
CY2021Q4	INDP	Accrued Board Fees Current AccruedBoardFeesCurrent	125333	usd
CY2022Q3	INDP	Delaware Franchise Taxes Payable Current DelawareFranchiseTaxesPayableCurrent	96697	usd
CY2022Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	61945	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	97779	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2782084	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4507676	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1174660	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.10
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y1M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	241103	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	621450	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	4.04
	INDP	Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm	P9Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	33237	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.46
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1762873	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M18D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	2500	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	531856	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	26.55
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1762873	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	12.60
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y9M18D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	2500	usd
CY2022Q3	us-gaap	Share Based Compensation ShareBasedCompensation	584041	usd
CY2021Q3	us-gaap	Share Based Compensation ShareBasedCompensation	795338	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2319619	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	836456	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5600000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y7M6D
CY2022Q3	INDP	Weighted Average Grant Date Fair Value Of Stock Options WeightedAverageGrantDateFairValueOfStockOptions	3.27
CY2022Q3	us-gaap	Share Price SharePrice	4.04
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	4.04
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M29D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.066	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2022Q3	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	1762873	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8258597	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8258597	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8258597	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8258597	shares
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	24476	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths	82388	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	106864	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3290	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	103574	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	98625	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4949	usd
	us-gaap	Payments For Rent PaymentsForRent	73069	usd
	us-gaap	Payments For Rent PaymentsForRent	19432	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	24356	usd
CY2021Q3	us-gaap	Payments For Rent PaymentsForRent	6701	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	71989	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	19160	usd

Files In Submission

Name	View Source	Status
0001493152-22-031392-index-headers.html	Edgar Link	pending
0001493152-22-031392-index.html	Edgar Link	pending
0001493152-22-031392.txt	Edgar Link	pending
0001493152-22-031392-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
indp-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
indp-20220930_def.xml	Edgar Link	unprocessable
indp-20220930_lab.xml	Edgar Link	unprocessable
indp-20220930_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
indp-20220930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INDP
Indaptus Therapeutics, Inc. Stock $indp

2022 Q4 Form 10-Q Financial Statement

#000149315222031392 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INDP Indaptus Therapeutics, Inc. Stock $indp

2022 Q4 Form 10-Q Financial Statement

#000149315222031392 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INDP
Indaptus Therapeutics, Inc. Stock $indp